Covance Not Cooling...
Health Care: Drugs
Pluristem Therapeutic (PSTI: NASDAQ)
$3.05 0.00 | 0.00%
05/17/13 - 03:59 PM ET
Company Cash Flow
| Jun 2012 | Jun 2011 | Jun 2010 | Jun 2009 | |
| Cash Flow From Operating Activities | ||||
|---|---|---|---|---|
| Net Income (Loss) | -14.79M | -10.85M | -7.45M | -6.64M |
| Operating Gains/Losses | -2.00K | 8.00K | 0.00 | 75.00K |
| Extraordinary Gains / Losses | 0.00 | 0.00 | 0.00 | 0.00 |
| (Increase) Decrease In Receivables | -561.00K | 671.00K | -322.00K | -247.00K |
| (Increase) Decrease in Inventories | 0.00 | 0.00 | 0.00 | 0.00 |
| (Increase) Decrease In Other Current Assets | 0.00 | 0.00 | 0.00 | 0.00 |
| (Decrease) Increase In Payables | -424.00K | 455.00K | 132.00K | -54.00K |
| (Decrease) Increase In Other Current Liabilities | 0.00 | 0.00 | 0.00 | 0.00 |
| (Increase) Decrease In Other Working Capital | 6.82M | 375.00K | 120.00K | -96.00K |
| Other Non-Cash Items | 4.98M | 3.54M | 1.85M | 2.28M |
| Net Cash From Continuing Operations | -3.28M | -5.76M | -5.41M | -4.26M |
| Net Cash From Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Provided By Investing Activities | ||||
| Net Cash From Total Operating Activities | -3.28M | -5.76M | -5.41M | -4.26M |
| Sale of Property, Plant & Equipment | 0.00 | 29.00K | 0.00 | 0.00 |
| Cash Used for Investing Activities | ||||
| Sale of Short-Term Investments | 998.00K | 898.00K | 1.60M | 0.00 |
| Purchases of Property, Plant & Equipment | -1.48M | -962.00K | -389.00K | -313.00K |
| Acquisitions | 0.00 | 0.00 | 0.00 | 0.00 |
| Purchases of Short-Term Investments | -21.03M | 0.00 | -2.50M | 0.00 |
| Other Cash from Investing Activities | -8.16M | 0.00 | 0.00 | 0.00 |
| Cash Provided by Financing Activities | ||||
| Net Cash From Investing Activities | -30.80M | -36.00K | -1.30M | 830.00K |
| Issuance of Debt | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Used for Financing Activities | ||||
| Issuance of Capital Stock | 632.00K | 47.06M | 5.96M | 5.46M |
| Repayment of Long-Term Debt | 0.00 | -24.00K | -8.00K | -14.00K |
| Repurchase of Capital Stock | 0.00 | 0.00 | 0.00 | 0.00 |
| Payment of Cash Dividends | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Financing Charges, Net | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Cash From Financing Activities | 632.00K | 47.04M | 5.95M | 5.45M |
| Effect of Exchange Rate Changes | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Change in Cash & Cash Equivalents | -33.44M | 41.25M | -756.00K | 2.02M |
Portfolios with PSTI
- Portfolio NameUser Type
- ContributorStocks Under-$10 Moving Hig...
- UserJaheer
- ContributorStocks Under-$10 Setting Up...
- UserBiotech88
- ContributorStocks Under-$10 Moving Hig...
- ContributorStocks Under-$10 Setting Up...
- ContributorStocks Under-$10 Setting Up...
- ContributorStocks Under-$10 Moving Hig...
- ContributorStocks Under-$10 Moving Hig...
- User0730
Latest PSTI Headlines from TheStreet
- Preclinical Research Shows PLX Cells May Be Effective In Treating Preeclampsia 05.13.13 | 03:05 am
- Pluristem Develops PLX-RAD Cells For Use In Hematology 05.07.13 | 03:05 am
- Pluristem To Present At Needham Healthcare And Oppenheimer Israeli Investment Conferences In May 2013 04.30.13 | 03:04 am
- Third Party Research Study Demonstrates Pluristem's PLX-PAD Cells' Safety In Human Lung Models Of Pulmonary Hypertension 04.29.13 | 03:04 am
- Pluristem Expands PLX Product Portfolio In Orthopedics And Sports Medicine 04.18.13 | 03:04 am
- United Therapeutics Receives Regulatory Approval To Commence Phase I Study Of Pluristem's PLX-PAD Cells For Pulmonary Arterial Hypertension 04.11.13 | 03:04 am
- Pluristem Announces Scientific And Investment Conferences For April 2013 04.10.13 | 02:04 am
- Pluristem Reports On The Progress Of Its Phase I/II Clinical Trial For The Treatment Of Muscle Injury 03.20.13 | 03:03 am
- United Therapeutics Moves Forward Towards A Phase I Study Of Pluristem's PLX-PAD Cells For Pulmonary Arterial Hypertension 02.26.13 | 09:02 am
- Pluristem Receives FDA Orphan Drug Status Designation For Treatment Of Aplastic Anemia 02.21.13 | 02:02 am
Press Releases for PSTI
- The Rosen Law Firm Announces Investigation Of Securities Claims Against Pluristem Therapeutics, Inc. --- PSTI - Business Wire 12.20.12 | 07:12 pm
- Pluristem Therapeutics Raises Approximately $5 Million In Private Placement Of Common Stock - Business Wire 10.12.10 | 08:10 am
- Data From Clinical Trials Show Pluristem’s Placenta-Derived Cell Therapy Is Safe And Improves Quality Of Life And Efficacy Measurements In Patients With Critical Limb Ischemia - Business Wire 09.14.10 | 08:09 am
- Pluristem’s Placenta Derived Cells Chosen By European Commission’s Seventh Framework Program (FP7) Study For Treatment Of Diastolic Heart Failure (DHF) In Type 2 Diabetic Patients - Business Wire 08.30.10 | 08:08 am
- Pluristem's PLX Cells Found To Be Effective In Treating Neuropathic And Inflammatory Pain - Business Wire 08.09.10 | 08:08 am
- Pluristem Appoints Diabetic Neuropathy And Vascular Disease Expert, Dr. Aristidis Veves, To Its Scientific Advisory Board - Business Wire 08.04.10 | 08:08 am
- Pluristem Is Advancing Toward Two Phase IIb Clinical Trials For Treatment Of Critical Limb Ischemia And Moderate-Severe Claudication - Business Wire 06.28.10 | 08:06 am
- Pluristem’s Off-The-Shelf Placenta-Derived Cell Therapies - The Focus Of Presentations At Upcoming Investor And Medical Conferences - Business Wire 05.20.10 | 08:05 am
Partner Headlines for PSTI
- Brainstorm's Breakthrough ALS Clinical Data Shows The Promise In Stem Cell Therapy - Seeking Alpha 03.28.13 | 09:03 am
- 3 Regenerative Medicine Companies That Could Deliver In 2013 - Seeking Alpha 01.22.13 | 09:01 am
- Orphan Status Update from Pluristem - Analyst Blog - Zacks 11.27.12 | 07:11 pm
- 4 Undervalued And Technically Oversold Healthcare Penny Stocks Poised To Bounce - Seeking Alpha 11.20.12 | 09:11 am
- 5 Bio-Pharmas On The Rise With Potential Groundbreaking And Lifesaving Treatments - Seeking Alpha 10.09.12 | 09:10 am
- Orphan Status Sought for PSTI Drug - Analyst Blog - NASDAQ 08.31.12 | 09:08 pm
- Orphan Status Sought for PSTI Drug - Analyst Blog - Zacks 08.31.12 | 06:08 pm
- Pluristem to Begin IC Phase II Trial - Analyst Blog - NASDAQ 08.24.12 | 10:08 pm
- Pluristem to Begin IC Phase II Trial - Analyst Blog - Zacks 08.24.12 | 06:08 pm
- Staring Down The Market With Futuristic Picks - Seeking Alpha 08.23.12 | 08:08 am
